期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 6, 期 9, 页码 550-552出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2009.113
关键词
-
类别
The cost of monoclonal antibody therapies for cancer is soaring out of control. Healthcare payers and patients are increasingly struggling to meet the high costs, which can be up to US$100,000 a year. A number of methods have been proposed to control these costs-government price controls on cancer drugs, biosimilars and novel drug pricing strategies. This article discusses what the impact of these strategies would be in terms of their ability to reduce costs and their effect on innovative cancer drug discovery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据